Imprimis Pharmaceuticals (NSDQ:IMMY) said today that it signed a 3-year exclusive sales agreement with Precision Lens. According to the deal, Precision Lens plans to deploy a sales team to expand Imprimis’ ophthalmic portfolio in 13 states across the U.S. Midwest.
Precision Lens said it will sell San Diego-based Imprimis’ Dropless Therapy, LessDrops combination eye drops and other eye care products.
Get the full story at our sister site, Drug Delivery Business News.
The post Imprimis, Precision Lens sign marketing and sales agreement appeared first on MassDevice.